Most tuberculosis (TB) tests still require a trip to the clinic. Now, new technology has made it possible to test people at home. This could be a big deal for South Africa, where much TB goes undiagnosed. Tiyese Jeranji unpacks the findings and implications of a recent study into such TB home testing.
In this open letter to Minister of Health Dr Joe Phaahla, TB activists call for the disease to be made a political priority and demand multisectoral departmental accountability. They outline six demands for implementation by the end of this year. The letter was submitted on the final day of the South African TB Conference being held this week in Durban.
Besides preventing illness and death, tuberculosis prevention therapy is estimated to be highly cost effective. Yet, uptake of the medication is not what it could be in South Africa. Tiyese Jeranji asks how much has changed since the Department of Health last year decided to make TB prevention therapy much more widely available.
South Africa is one of only six countries to ever meet their “fair share target” for funding tuberculosis (TB) research, according to a new report. In absolute terms however, South Africa’s contribution is small change compared to investments into TB research made by the top two contributors, the United States government and the Bill and Melinda Gates Foundation. Catherine Tomlinson unpacks what the report tells us about investment in TB research in South Africa.
Tuberculosis (TB) preventive therapy has been transformed in recent years, with treatment duration having been cut from six or more months to just three or one. Progress in developing new treatments to prevent drug-resistant forms of TB has however lagged behind, especially in children. Elri Voigt unpacks findings from a major new TB prevention study presented at the Union World Conference on Lung Health last week and plans for another important preventive therapy trial set to start soon.
At the age of 19 Phumeza Tisile contracted multidrug-resistant tuberculosis. For four years she battled the disease, losing her hearing in the process. At one stage, a doctor told her to visit a priest and prepare her soul for death. Recently, Tisile (now 33) made it on to TIME magazine’s 2023 TIME100 Next list, as one of 100 emerging leaders round the world who are “shaping the future and defining the next generation of leadership”. Sue Segar chatted to Tisile about her remarkable journey.
Several of the world’s most important tuberculosis clinical trials of the last two decades were done in part or entirely in South Africa. Tiyese Jeranji chatted to some leading researchers about where the country’s clinical trial capacity comes from and what is needed to maintain and improve it.
An estimated 54 000 people died of tuberculosis in South Africa in 2022 and around 280 000 fell ill with the disease, according to just-released figures from the World Health Organization. Catherine Tomlinson unpacks the figures and what they mean for the country’s TB response.
A recent study published in the journal Clinical Infectious Diseases found that there was an association between healthcare workers’ exposure to high levels of carbon dioxide (CO2) and their risk of being exposed to tuberculosis (TB). Elri Voigt unpacks the study’s findings and asks experts how CO2 monitors work, how well they predict the risk of TB exposure, and in which settings these monitors might be most useful.
A new report from the Lancet Commission on Tuberculosis (TB) titled ‘Scientific advances and the end of tuberculosis’ makes several recommendations for how governments should go about fighting the deadly, but curable, disease. Spotlight editor Marcus Low puts the Spotlight on how South Africa’s TB programme is measuring up against the recommendations.
The second United Nations High-Level Meeting on Tuberculosis is taking place in New York today. Sihle Mahonga Ndawonde argues that better TB data and more transparency are needed in South Africa if we are to get and stay on the road to meeting the ambitious targets set and endorsed at this UN meeting.
Professor Valerie Mizrahi, a world-leading tuberculosis researcher and director of the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town, is retiring at the end of the year. Biénne Huisman sat down with Mizrahi to talk about her journey in TB research, passing the baton to a new generation of researchers, and how she helped build a research ecosystem that brings together specialists across the basic, clinical, and public health sciences.
